IDXG
Interpace Biosciences, Inc.
Price Chart
Latest Quote
$1.70
+0.02 (+1.19%)
Current Price
| Previous Close | $1.68 |
| Open | $1.68 |
| Day High | $1.70 |
| Day Low | $1.68 |
| Volume | 3,211 |
Stock Information
| Shares Outstanding | 27.70M |
| Total Debt | $1.08M |
| Cash Equivalents | $2.65M |
| Revenue | $36.24M |
| Net Income | $24.06M |
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Market Cap | $47.09M |
| P/E Ratio | 1.95 |
| EPS (TTM) | $0.87 |
| Exchange | OID |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $45.52M |
| Sales | $36.24M |
| Income | $24.06M |
| Book/sh | $0.83 |
| Cash/sh | $0.10 |
| Employees | 102 |
Financial Ratios
| Quick Ratio | 2.16 |
| Current Ratio | 2.52 |
| Debt/Eq | 4.68 |
| EPS Growth TTM | -56.20% |
Returns & Margins
| ROA | 10.64% |
| ROE | 213.88% |
| Gross Margin | 62.53% |
| Operating Margin | 12.43% |
| Profit Margin | 65.25% |
Ownership
| Insider Ownership | 85.18% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -11.33 |
| PEG | 0.36 |
| P/S | 1.30 |
| P/B | 2.04 |
Analyst Data
| Recommendation | none |
Technical Indicators
| SMA20 | $1.69 |
| SMA50 | $1.86 |
| SMA200 | $1.46 |
| RSI | 46.15 |
| ATR | 0.0936 |
| Shares Float | 3.47M |
| Short Float | 1.18% |
| Short Ratio | 0.19 |
| Volatility | 0.57 |
| Rel Volume | 1.43 |
Performance History
| Week | +8.28% |
| Month | -6.59% |
| Quarter | -0.70% |
| 6 Months | +41.67% |
| YTD | +42.86% |
| Year | +126.97% |
| 10 Years | +53.15% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-24 | $1.70 | 6,900 |
| 2026-06-23 | $1.68 | 200 |
| 2026-06-22 | $1.63 | 4,400 |
| 2026-06-18 | $1.67 | 900 |
| 2026-06-17 | $1.64 | 200 |
| 2026-06-16 | $1.57 | 12,100 |
| 2026-06-15 | $1.58 | 2,600 |
| 2026-06-12 | $1.60 | 4,600 |
| 2026-06-11 | $1.65 | 2,600 |
| 2026-06-10 | $1.76 | 7,300 |
| 2026-06-09 | $1.74 | 6,600 |
| 2026-06-08 | $1.68 | 1,900 |
| 2026-06-05 | $1.67 | 15,500 |
| 2026-06-04 | $1.79 | 15,800 |
| 2026-06-03 | $1.75 | 1,600 |
| 2026-06-02 | $1.76 | 3,000 |
| 2026-06-01 | $1.72 | 1,300 |
| 2026-05-29 | $1.70 | 500 |
| 2026-05-28 | $1.80 | 2,300 |
| 2026-05-27 | $1.80 | 5,900 |
| 2026-05-26 | $1.80 | 8,400 |
About Interpace Biosciences, Inc.
Interpace Biosciences, Inc. provides molecular diagnostic tests and pathology services for evaluating cancer risk in the United States. It offers ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. The company also provides ThyraMIR v2, which assesses thyroid nodules for malignancy risk using a proprietary microRNA gene expression classifier. It primarily serves physicians, cancer centers, clinics, laboratories, pathology groups, and hospitals. The company was formerly known as Interpace Diagnostics Group, Inc. and changed its name to Interpace Biosciences, Inc. in November 2019. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.
đ° Latest News
No news articles available at the moment. Check back later for updates on IDXG.
Period:
Loading...
Income Statement (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $16,253,000 | $14,240,000 | $11,375,000 | $12,132,000 |
| Cost Of Revenue | $17,001,000 | $14,980,000 | $13,607,000 | $14,314,000 |
| Total Revenue | $46,926,000 | $40,036,000 | $31,838,000 | $33,117,000 |
| Operating Revenue | $46,926,000 | $40,036,000 | $31,838,000 | $33,117,000 |
| Expenses | ||||
| Interest Expense | $659,000 | $1,008,000 | $1,008,000 | $1,040,000 |
| Total Expenses | $38,818,000 | $36,073,000 | $35,678,000 | $38,881,000 |
| Other Income Expense | $-499,000 | $-674,000 | $-988,000 | $-938,000 |
| Other Non Operating Income Expenses | $-499,000 | $-667,000 | $-1,211,000 | $-379,000 |
| Net Non Operating Interest Income Expense | $-659,000 | $-1,008,000 | $-1,008,000 | $-1,040,000 |
| Interest Expense Non Operating | $659,000 | $1,008,000 | $1,008,000 | $1,040,000 |
| Operating Expense | $21,817,000 | $21,093,000 | $22,071,000 | $24,567,000 |
| Selling And Marketing Expense | $11,655,000 | $10,233,000 | $9,125,000 | $9,177,000 |
| General And Administrative Expense | $9,486,000 | $9,363,000 | $10,973,000 | $10,705,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $6,946,000 | $2,264,000 | $-5,865,000 | $-7,037,000 |
| Net Interest Income | $-659,000 | $-1,008,000 | $-1,008,000 | $-1,040,000 |
| Normalized Income | $6,946,000 | $2,270,951 | $-6,041,170 | $-6,528,869 |
| Net Income From Continuing And Discontinued Operation | $6,702,000 | $1,954,000 | $-21,958,000 | $-14,943,000 |
| Total Operating Income As Reported | $8,108,000 | $3,956,000 | $-3,617,000 | $-6,336,000 |
| Net Income Common Stockholders | $6,238,000 | $1,954,000 | $-21,958,000 | $-14,943,000 |
| Net Income | $6,702,000 | $1,954,000 | $-21,958,000 | $-14,943,000 |
| Net Income Including Noncontrolling Interests | $6,702,000 | $1,954,000 | $-21,958,000 | $-14,943,000 |
| Net Income Discontinuous Operations | $-244,000 | $-310,000 | $-16,093,000 | $-7,906,000 |
| Net Income Continuous Operations | $6,946,000 | $2,264,000 | $-5,865,000 | $-7,037,000 |
| Pretax Income | $6,950,000 | $2,281,000 | $-5,836,000 | $-7,742,000 |
| Special Income Charges | $0 | $-7,000 | $223,000 | $-559,000 |
| Operating Income | $8,108,000 | $3,963,000 | $-3,840,000 | $-5,764,000 |
| Depreciation Amortization Depletion Income Statement | $0 | $861,000 | $1,270,000 | $3,192,000 |
| Depreciation And Amortization In Income Statement | $0 | $861,000 | $1,270,000 | $3,192,000 |
| Amortization Of Intangibles Income Statement | $0 | $861,000 | $1,270,000 | $3,192,000 |
| Gross Profit | $29,925,000 | $25,056,000 | $18,231,000 | $18,803,000 |
| Per Share | ||||
| Diluted EPS | $0.40 | $0.18 | $-5.18 | $-3.61 |
| Basic EPS | $1.42 | $0.19 | $-5.18 | $-3.61 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $-49 | $46,830 | $-50,869 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $8,357,000 | $4,897,000 | $-1,549,000 | $-769,000 |
| Total Unusual Items | $0 | $-7,000 | $223,000 | $-559,000 |
| Total Unusual Items Excluding Goodwill | $0 | $-7,000 | $223,000 | $-559,000 |
| Reconciled Depreciation | $748,000 | $1,601,000 | $3,502,000 | $5,374,000 |
| EBITDA (Bullshit earnings) | $8,357,000 | $4,890,000 | $-1,326,000 | $-1,328,000 |
| EBIT | $7,609,000 | $3,289,000 | $-4,828,000 | $-6,702,000 |
| Diluted Average Shares | $15,734,000 | $4,364,000 | $4,238,000 | $4,135,000 |
| Basic Average Shares | $4,387,000 | $4,317,000 | $4,238,000 | $4,135,000 |
| Diluted NI Availto Com Stockholders | $6,238,000 | $1,954,000 | $-21,958,000 | $-14,943,000 |
| Preferred Stock Dividends | $464,000 | - | - | - |
| Tax Provision | $4,000 | $17,000 | $29,000 | $-705,000 |
| Restructuring And Mergern Acquisition | $0 | $7,000 | $-223,000 | $559,000 |
| Amortization | $0 | $861,000 | $1,270,000 | $3,192,000 |
| Research And Development | $676,000 | $636,000 | $703,000 | $1,493,000 |
| Selling General And Administration | $21,141,000 | $19,596,000 | $20,098,000 | $19,882,000 |
| Other Gand A | $9,486,000 | $9,363,000 | $10,973,000 | $10,705,000 |
| Otherunder Preferred Stock Dividend | - | - | - | $0 |
Fetched: 2026-02-02
Balance Sheet (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-2,217,000 | $-55,539,000 | $-63,933,000 | $-44,550,000 |
| Total Assets | $14,792,000 | $13,116,000 | $15,979,000 | $38,427,000 |
| Total Non Current Assets | $3,019,000 | $2,699,000 | $3,825,000 | $26,261,000 |
| Other Non Current Assets | $45,000 | $45,000 | $45,000 | $22,528,000 |
| Current Assets | $11,773,000 | $10,417,000 | $12,154,000 | $12,166,000 |
| Other Current Assets | $22,000 | $24,000 | $180,000 | $70,000 |
| Prepaid Assets | $535,000 | $590,000 | $390,000 | $584,000 |
| Inventory | $1,211,000 | $1,227,000 | $1,224,000 | $825,000 |
| Receivables | $8,544,000 | $5,078,000 | $5,032,000 | $4,672,000 |
| Accounts Receivable | $8,544,000 | $5,078,000 | $5,032,000 | $4,672,000 |
| Cash Cash Equivalents And Short Term Investments | $1,461,000 | $3,498,000 | $4,828,000 | $2,672,000 |
| Cash And Cash Equivalents | $1,461,000 | $3,498,000 | $4,828,000 | $2,672,000 |
| Goodwill And Other Intangible Assets | - | $0 | $861,000 | $2,132,000 |
| Restricted Cash | - | $0 | $500,000 | $250,000 |
| Other Intangible Assets | - | - | $861,000 | $2,132,000 |
| Assets Held For Sale Current | - | - | $0 | $3,093,000 |
| Allowance For Doubtful Accounts Receivable | - | - | $0 | $-72,000 |
| Gross Accounts Receivable | - | - | $5,032,000 | $4,744,000 |
| Debt | ||||
| Net Debt | $2,829,000 | $5,845,000 | $8,837,000 | $6,770,000 |
| Total Debt | $5,856,000 | $11,192,000 | $16,091,000 | $10,724,000 |
| Long Term Debt And Capital Lease Obligation | $1,183,000 | $5,715,000 | $13,013,000 | $9,962,000 |
| Current Debt And Capital Lease Obligation | $4,673,000 | $5,477,000 | $3,078,000 | $762,000 |
| Current Debt | $4,290,000 | $5,100,000 | $2,500,000 | - |
| Other Current Borrowings | $4,290,000 | $5,100,000 | $2,500,000 | - |
| Long Term Debt | - | $4,243,000 | $11,165,000 | $9,442,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $17,009,000 | $68,655,000 | $79,051,000 | $80,845,000 |
| Total Non Current Liabilities Net Minority Interest | $6,394,000 | $57,219,000 | $64,768,000 | $65,163,000 |
| Other Non Current Liabilities | $5,211,000 | $4,968,000 | $5,219,000 | $5,960,000 |
| Current Liabilities | $10,615,000 | $11,436,000 | $14,283,000 | $15,682,000 |
| Other Current Liabilities | $660,000 | $660,000 | $858,000 | $3,228,000 |
| Payables And Accrued Expenses | $5,282,000 | $5,299,000 | $10,347,000 | $11,692,000 |
| Payables | $1,921,000 | $1,805,000 | $1,312,000 | $1,596,000 |
| Total Tax Payable | $262,000 | $261,000 | $262,000 | $222,000 |
| Accounts Payable | $1,659,000 | $1,544,000 | $1,050,000 | $1,374,000 |
| Liabilities Heldfor Sale Non Current | - | - | $0 | $2,705,000 |
| Interest Payable | - | - | $0 | $120,000 |
| Non Current Deferred Liabilities | - | - | - | $13,000 |
| Current Deferred Liabilities | - | - | - | $40,000 |
| Equity | ||||
| Common Stock Equity | $-2,217,000 | $-55,539,000 | $-63,072,000 | $-42,418,000 |
| Total Equity Gross Minority Interest | $-2,217,000 | $-55,539,000 | $-63,072,000 | $-42,418,000 |
| Stockholders Equity | $-2,217,000 | $-55,539,000 | $-63,072,000 | $-42,418,000 |
| Retained Earnings | $-235,380,000 | $-242,082,000 | $-249,017,000 | $-227,059,000 |
| Preferred Securities Outside Stock Equity | $0 | $46,536,000 | $46,536,000 | $46,536,000 |
| Preferred Stock Equity | - | - | - | $46,536,000 |
| Other | ||||
| Treasury Shares Number | $130,340 | $96,044 | $71,120 | $32,757 |
| Ordinary Shares Number | $4,409,323 | $4,351,445 | $4,296,710 | $4,195,412 |
| Share Issued | $4,539,663 | $4,447,489 | $4,367,830 | $4,228,169 |
| Tangible Book Value | $-2,217,000 | $-55,539,000 | $-63,933,000 | $-44,550,000 |
| Invested Capital | $2,073,000 | $-46,196,000 | $-49,407,000 | $-32,976,000 |
| Working Capital | $1,158,000 | $-1,019,000 | $-2,129,000 | $-3,516,000 |
| Capital Lease Obligations | $1,566,000 | $1,849,000 | $2,426,000 | $1,282,000 |
| Total Capitalization | $-2,217,000 | $-51,296,000 | $-51,907,000 | $-32,976,000 |
| Treasury Stock | $2,054,000 | $2,008,000 | $1,976,000 | $1,868,000 |
| Additional Paid In Capital | $234,811,000 | $188,146,000 | $187,516,000 | $186,106,000 |
| Capital Stock | $406,000 | $405,000 | $405,000 | $403,000 |
| Common Stock | $406,000 | $405,000 | $405,000 | $403,000 |
| Preferred Stock | $0 | $0 | - | $46,536,000 |
| Long Term Capital Lease Obligation | $1,183,000 | $1,472,000 | $1,848,000 | $520,000 |
| Current Capital Lease Obligation | $383,000 | $377,000 | $578,000 | $762,000 |
| Current Accrued Expenses | $3,361,000 | $3,494,000 | $9,035,000 | $10,096,000 |
| Net PPE | $2,974,000 | $2,654,000 | $2,919,000 | $1,601,000 |
| Accumulated Depreciation | $-2,845,000 | $-2,544,000 | $-2,379,000 | $-2,220,000 |
| Gross PPE | $5,819,000 | $5,198,000 | $5,298,000 | $3,821,000 |
| Leases | $483,000 | $269,000 | $175,000 | $175,000 |
| Other Properties | $1,613,000 | $1,864,000 | $2,439,000 | $1,284,000 |
| Machinery Furniture Equipment | $3,723,000 | $3,065,000 | $2,684,000 | $2,362,000 |
| Properties | $0 | $0 | $0 | $0 |
| Raw Materials | $1,211,000 | $1,227,000 | $1,224,000 | - |
| Line Of Credit | - | $0 | $2,500,000 | - |
| Other Inventories | - | - | $1,224,000 | $825,000 |
| Non Current Deferred Revenue | - | - | - | $13,000 |
| Current Deferred Revenue | - | - | - | $40,000 |
| Goodwill | - | - | - | $8,433,000 |
Fetched: 2026-02-02
Cash Flow Statement (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $3,770,000 | $3,319,000 | $-8,014,000 | $-9,073,000 |
| Operating Activities | ||||
| Operating Cash Flow | $4,646,000 | $3,789,000 | $-7,692,000 | $-8,719,000 |
| Cash Flow From Continuing Operating Activities | $4,646,000 | $3,789,000 | $-7,692,000 | $-8,719,000 |
| Operating Gains Losses | - | - | - | $63,000 |
| Investing Activities | ||||
| Capital Expenditure | $-876,000 | $-470,000 | $-322,000 | $-354,000 |
| Investing Cash Flow | $-876,000 | $-87,000 | $6,206,000 | $-315,000 |
| Cash Flow From Continuing Investing Activities | $-876,000 | $-87,000 | $6,206,000 | $-315,000 |
| Financing Activities | ||||
| Financing Cash Flow | $-5,807,000 | $-5,032,000 | $3,000,000 | $8,976,000 |
| Cash Flow From Continuing Financing Activities | $-5,807,000 | $-5,032,000 | $3,000,000 | $8,976,000 |
| Net Other Financing Charges | $-161,000 | $-2,500,000 | - | $-435,000 |
| Repurchase Of Capital Stock | - | $-32,000 | $-108,000 | $0 |
| Issuance Of Capital Stock | - | $0 | $108,000 | $335,000 |
| Net Common Stock Issuance | - | $0 | $108,000 | $335,000 |
| Common Stock Issuance | - | $0 | $108,000 | $335,000 |
| Net Preferred Stock Issuance | - | - | - | $0 |
| Preferred Stock Issuance | - | - | - | $0 |
| Other | ||||
| Repayment Of Debt | $-5,600,000 | $-2,500,000 | $0 | $-7,924,000 |
| Interest Paid Supplemental Data | $625,000 | $1,092,000 | $971,000 | $369,000 |
| Income Tax Paid Supplemental Data | $274,000 | $270,000 | $251,000 | $424,000 |
| End Cash Position | $1,461,000 | $3,498,000 | $4,828,000 | $3,314,000 |
| Beginning Cash Position | $3,498,000 | $4,828,000 | $3,314,000 | $3,372,000 |
| Changes In Cash | $-2,037,000 | $-1,330,000 | $1,514,000 | $-58,000 |
| Proceeds From Stock Option Exercised | $-46,000 | $-32,000 | $-108,000 | $0 |
| Net Issuance Payments Of Debt | $-5,600,000 | $-2,500,000 | $3,000,000 | $9,076,000 |
| Net Short Term Debt Issuance | $-5,600,000 | $-2,500,000 | $1,000,000 | $1,500,000 |
| Short Term Debt Payments | $-5,600,000 | $-2,500,000 | $0 | - |
| Net Business Purchase And Sale | $0 | $383,000 | $6,528,000 | $0 |
| Sale Of Business | $0 | $383,000 | $6,528,000 | $0 |
| Net PPE Purchase And Sale | $-876,000 | $-470,000 | $-322,000 | $-315,000 |
| Purchase Of PPE | $-876,000 | $-470,000 | $-322,000 | $-354,000 |
| Change In Working Capital | $-3,676,000 | $-1,235,000 | $-3,991,000 | $-1,131,000 |
| Change In Other Current Liabilities | $-237,000 | $-109,000 | $-971,000 | $-149,000 |
| Change In Other Current Assets | $73,000 | $-89,000 | $-182,000 | $-90,000 |
| Change In Payables And Accrued Expense | $-46,000 | $-1,264,000 | $-2,705,000 | $-3,040,000 |
| Change In Accrued Expense | $-166,000 | $-1,753,000 | $-1,970,000 | $-1,223,000 |
| Change In Payable | $120,000 | $489,000 | $-735,000 | $-1,817,000 |
| Change In Account Payable | $120,000 | $489,000 | $-735,000 | $-1,817,000 |
| Change In Receivables | $-3,466,000 | $227,000 | $-133,000 | $2,148,000 |
| Changes In Account Receivables | $-3,466,000 | $227,000 | $-133,000 | $2,148,000 |
| Other Non Cash Items | $581,000 | $839,000 | $1,147,000 | $715,000 |
| Stock Based Compensation | $291,000 | $630,000 | $1,304,000 | $1,368,000 |
| Depreciation Amortization Depletion | $748,000 | $1,601,000 | $3,502,000 | $5,374,000 |
| Depreciation And Amortization | $748,000 | $1,601,000 | $3,502,000 | $5,374,000 |
| Depreciation | $748,000 | $1,601,000 | $3,502,000 | - |
| Net Income From Continuing Operations | $6,702,000 | $1,954,000 | $-21,958,000 | $-14,943,000 |
| Issuance Of Debt | - | $0 | $3,000,000 | $17,000,000 |
| Common Stock Payments | - | $-32,000 | $-108,000 | $0 |
| Short Term Debt Issuance | - | $0 | $1,000,000 | - |
| Net Long Term Debt Issuance | - | $0 | $2,000,000 | $9,076,000 |
| Long Term Debt Issuance | - | $0 | $2,000,000 | $17,000,000 |
| Asset Impairment Charge | - | $0 | $12,397,000 | $-140,000 |
| Deferred Tax | - | $0 | $-93,000 | $38,000 |
| Deferred Income Tax | - | $0 | $-93,000 | $38,000 |
| Long Term Debt Payments | - | - | $0 | $-7,924,000 |
| Sale Of PPE | - | - | $0 | $39,000 |
| Provisionand Write Offof Assets | - | - | - | $0 |
| Gain Loss On Investment Securities | - | - | - | $50,000 |
| Gain Loss On Sale Of Business | - | - | - | $13,000 |
Fetched: 2026-02-02